CA2749824C - Identification de nouvelles toxines antagonistes de canaux calciques type-t a visee analgesique - Google Patents

Identification de nouvelles toxines antagonistes de canaux calciques type-t a visee analgesique Download PDF

Info

Publication number
CA2749824C
CA2749824C CA2749824A CA2749824A CA2749824C CA 2749824 C CA2749824 C CA 2749824C CA 2749824 A CA2749824 A CA 2749824A CA 2749824 A CA2749824 A CA 2749824A CA 2749824 C CA2749824 C CA 2749824C
Authority
CA
Canada
Prior art keywords
peptide
tgy
channel
sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2749824A
Other languages
English (en)
French (fr)
Other versions
CA2749824A1 (fr
Inventor
Emmanuel Bourinet
Pierre Escoubas
Fabrice Marger
Joel Nargeot
Michel Lazdunski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Université Côte d'Azur
Original Assignee
Centre National de la Recherche Scientifique
Université Côte d'Azur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Université Côte d'Azur filed Critical Centre National de la Recherche Scientifique
Publication of CA2749824A1 publication Critical patent/CA2749824A1/fr
Application granted granted Critical
Publication of CA2749824C publication Critical patent/CA2749824C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
CA2749824A 2009-01-15 2010-01-15 Identification de nouvelles toxines antagonistes de canaux calciques type-t a visee analgesique Expired - Fee Related CA2749824C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR09/00174 2009-01-15
FR0900174A FR2940973B1 (fr) 2009-01-15 2009-01-15 Identification de nouvelles toxines antagonistes de canaux calcique type-t a visee analgesique
PCT/FR2010/000037 WO2010081971A1 (fr) 2009-01-15 2010-01-15 Identification de nouvelles toxines antagonistes de canaux calciques type-t a visee analgesique

Publications (2)

Publication Number Publication Date
CA2749824A1 CA2749824A1 (fr) 2010-07-22
CA2749824C true CA2749824C (fr) 2017-05-02

Family

ID=40834515

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2749824A Expired - Fee Related CA2749824C (fr) 2009-01-15 2010-01-15 Identification de nouvelles toxines antagonistes de canaux calciques type-t a visee analgesique

Country Status (7)

Country Link
US (1) US8664179B2 (enExample)
EP (1) EP2387581B1 (enExample)
JP (1) JP5519702B2 (enExample)
CA (1) CA2749824C (enExample)
ES (1) ES2524564T3 (enExample)
FR (1) FR2940973B1 (enExample)
WO (1) WO2010081971A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014045126A2 (en) * 2012-09-18 2014-03-27 Uti Limited Partnership Treatment of pain by inhibition of usp5 de-ubiquitinase
US20220089663A1 (en) * 2019-01-18 2022-03-24 Memorial Sloan Kettering Cancer Center PROTEINS AND FLUOROPHORE-CONTAINING COMPOUNDS SELECTIVE FOR NaV1.7
US20230241259A1 (en) * 2020-06-10 2023-08-03 Memorial Sloan Kettering Cancer Center IMAGING COMPOUNDS SELECTIVE FOR NaV1.7

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776896A (en) * 1996-01-03 1998-07-07 Zeneca Limited Analgesic peptides from venom of grammostola spatulata and use thereof
US5756663A (en) * 1996-01-03 1998-05-26 Zeneca Limited Antiarrhythmic peptide from venom of spider Grammostola spatulata
AU6109698A (en) 1998-02-20 1999-09-06 Zeneca Limited Analgesic peptides from venom of (grammostola spatulata) and use thereof

Also Published As

Publication number Publication date
JP5519702B2 (ja) 2014-06-11
WO2010081971A1 (fr) 2010-07-22
JP2012514992A (ja) 2012-07-05
EP2387581A1 (fr) 2011-11-23
EP2387581B1 (fr) 2014-10-08
CA2749824A1 (fr) 2010-07-22
FR2940973A1 (fr) 2010-07-16
FR2940973B1 (fr) 2013-05-24
US8664179B2 (en) 2014-03-04
ES2524564T3 (es) 2014-12-10
US20120040909A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
US9062125B2 (en) Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
Park et al. Activation of protein kinase C augments T‐type Ca2+ channel activity without changing channel surface density
WO1991018981A2 (fr) Facteurs de croissance neurotropes comprenant un peptide homeoboite
EP2387581B1 (fr) Identification de nouvelles toxines antagonistes de canaux calciques type-t a visee analgesique
CA2806471C (fr) Nouveaux peptides avec des effets analgesiques et inhibant les canaux asic
WO2002002595A9 (fr) Peptides lineaires amphipathiques et les compositions les contenant
EP0977844B1 (fr) Canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications
EP1003784A1 (fr) Polypeptides utiles dans la regeneration du systeme nerveux
US10179802B2 (en) Conotoxin peptide κ-CPTX-BTL04, preparation method therefor, and uses thereof
Fournier et al. Conformational and biological studies of neuropeptide Y analogs containing structural alterations.
WO1997004094A1 (fr) Sequences nucleiques codant pour des recepteurs de la melatonine et leurs applications
EP1058726A2 (fr) Nouvelle famille de canaux potassium de mammiferes mecanosensibles et actives par les acides gras polyinsatures et leur utilisation notamment pour le criblage de drogues
RU2521657C1 (ru) Анальгетический пептид из морской анемоны urticina grebelnyi
WO2002024142A2 (fr) Utilisation de modulateurs de recepteurs a l'adenosine pour reguler la fonction des netrines et/ou de leurs recepteurs
Kompella α-Conotoxins targeting neuronal nAChRs: understanding molecular pharmacology and potential therapeutics.
FR2701265A1 (fr) Nouveaux polypeptides ayant une activité de récepteur sérotoninergique, acides nucléiques codant pour ces polypeptides et utilisations.
FR2682875A1 (fr) Utilisation de l'acide polysialique alpha2-8 pour la regulation de l'action des peptides homeoboites.
Yasuda et al. Voltage-gated calcium channels in nociception
EP1263953A2 (fr) Famille de canaux potassium humains mecanosensibles et actives par les acides gras polyinsatures et leur utilisation
FR3092992A1 (fr) Inhibiteur d’acyl-thioestérases pour le traitement et/ou la prévention de la maladie de huntington
WO2005081613A2 (en) Pharmaceutical compositions of peptides secreted by the venom glands of snakes
FR2759372A1 (fr) Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications
THIROUIN et al. BDNF AND SUMO PATHWAY MODULATE GEPHYRIN SCAFFOLD TO DOWNREGULATE GABAERGIC TRANSMISSION AFTER ISCHEMIA
Flynn et al. Wednesday, February 24, 2010 693a
EP3125917A1 (en) Cell-permeable peptide system for treating diseases caused by glutamate excitotoxicity

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141128

MKLA Lapsed

Effective date: 20210115